[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"antibiotics\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:antibiotics":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,45,69,99,126,153,181,210],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100413909","phase-4-antibiotics-as-adjuncts-to-periodontal-therapypharmacokinetic-considerations-and-dosing-strategies-100413909",false,"NCT04669717","Antibiotics as Adjuncts to Periodontal Therapy:Pharmacokinetic Considerations and Dosing Strategies","Pharmacokinetic Considerations and Dosing Strategies of Amoxicillin and Metronidazole or Azithromycin as Adjunct to Non-surgical Periodontal Therapy. A Randomized,6-month, Parallel-group, Clinical Trial.","AMA","Inclusion Criteria:\n\n* Informed Consent as documented by signature\n* Aged 18-80 years old with need of periodontal treatment associated with adjunctive antibiotic therapy\n* Presence of at least 30% of the teeth in the mouth with PD\\>6mm and BOP\n\nExclusion Criteria:\n\n* Persons with systemic illnesses (uncontrolled diabetes mellitus, cancer, human immunodeficiency virus, bone metabolic diseases or disorders that compromise wound healing, radiation, or immunosuppressive therapy)\n* Pregnancy or lactation\n* Persons who had taken AB within the previous 2 months\n* Persons who are taking nonsteroidal anti-inflammatory drugs\n* Persons who have a confirmed or suspected intolerance to 5-nitroimidazole derivatives or amoxicillin or macrolides\n* Previous periodontal therapy the last 1 year\n* Known or suspected non-compliance, drug or alcohol abuse\n* Inability to follow due to language problems, psychological disorders, dementia, etc. of the participant\n* Participants not willing to attend regular dental maintenance visits and follow-up evaluations\n* Participation in another study with investigational drug within the 30 days preceding and during the present study",true,"ALL","18 Years","80 Years",{"count":22,"type":23},45,"ESTIMATED","INTERVENTIONAL",[26],"PHASE4","Periodontitits is a bacteria induced inflammatory disease that destroys the supporting tissues of the tooth and leads to tooth loss. Treatment consists mainly of the mechanical cleaning of the tooth surfaces in order to remove the bacterial deposits (plaque and calculus). This procedure can reduce the level of pathogenic bacteria but it can not eradicate them. In severe cases, for the complete resolution of the disease, the elimantion of certain species of bacteria is needed. In order to achieve that, the combination of different regimens of antibiotics adjunctive to the mechanical treatment has been proposed. However, dosage and duration of antimicrobial therapy should be optimal and not excessive as issues may arise related to increased antimicrobial resistance in the population and the individual due to habitual prescription of wide-spectrum antibiotic regimens, horizontal gene transfer and genetic mutation.\n\nIn the present study, in an effort to optimize the dosage and duration of the antimicrobial regimen, we will determine the pharmacokinetics (PK) and pharmacodynamic (PD) properties of the MET-AMO combination and of AZI in Gingival Crevicular Fluid (GCF), saliva and serum in severe periodontitis patients during and after either a 3-day or a 7-day course of treatment.",[29,30,31],"Periodontal Diseases","Antibiotics","Pharmacokinetics","RECRUITING","2026-04-28",{"date":35,"type":36},"2026-04-29","ACTUAL",{"date":38,"type":36},"2021-09-01",{"date":40,"type":23},"2028-12-01",{"name":42,"class":43},"University of Geneva, Switzerland","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":24,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":44},"100611929","antibiotic-prophylaxis-for-ureteroscopy-with-a-negative-pressure-suction-sheath-100611929","NCT07246967","Antibiotic Prophylaxis for Ureteroscopy With a Negative Pressure Suction Sheath","An International Multicenter Study on the Antimicrobial Prophylaxis Strategy for Flexible Ureteroscopic Lithotripsy Combined With a Flexible Negative Pressure Suction Sheath","Inclusion Criteria:\n\n1. Age 18-75 years.\n2. Diagnosed by CT with renal and\u002For upper ureteral stones, with the longest stone diameter being ≤2cm.\n3. Scheduled to undergo fURS lithotripsy.\n4. No preoperative symptoms of infection such as chills and fever, and the most recent preoperative urine culture is negative.\n5. No immunosuppressive status and no urinary flow obstruction caused by anatomical abnormalities.\n6. No use of long-acting antimicrobial agents within 7 days prior to surgery, and no use of intermediate or short-acting antimicrobial agents within 72 hours prior to surgery.\n7. Has signed and dated an informed consent form, indicating that the patient or their legal representative has been fully informed about the study-related information and has agreed to participate.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. Allergy to the investigational drug(s).\n3. Participation in other clinical trials within 30 days.\n4. Presence of other active infection foci requiring antimicrobial treatment.\n5. Concomitant severe systemic diseases, such as cardiac or pulmonary disease, malignant tumors, and immunodeficiency states.\n6. Congenital malformations of the urinary tract.\n7. History of kidney transplantation or urinary diversion surgery.\n8. Unable to provide samples or complete follow-up according to the study protocol.\n9. Unable to provide informed consent.\n10. Inability to achieve complete placement of the flexible negative-pressure suction sheath.\n11. Any other conditions that the investigator deems unsuitable for participation in this study.\n12. History of diabetes mellitus, immunocompromised.\n13. Renal insufficiency, neurogenic bladder.\n14. Recent preoperative history of stone-related fever.\n15. Long-term indwelling urinary drainage tube.\n16. Urine white blood cells \\>5\u002FHPF (High Power Field) or positive for urine nitrites.\n17. Large stone burden (e.g., staghorn calculus) or moderate to severe hydronephrosis.\n18. Imaging findings showing turbid urine in the renal pelvis where pyonephrosis or infectious stones cannot be excluded.","75 Years",{"count":54,"type":23},500,[56],"NA","This study, as a prospective, randomized, controlled, non-inferiority, international multicenter clinical trial, aims to evaluate whether a strategy of no antimicrobial prophylaxis is non-inferior to the traditional single-dose prophylaxis regimen in patients with a low risk of infection undergoing single-use flexible ureteroscopic lithotripsy combined with a flexible negative-pressure suction sheath. It is anticipated that this will have a substantial impact on infection prevention strategies in urological surgery.",[59,30],"Urolithiasis","2026-04-22",{"date":62,"type":36},"2026-04-23",{"date":64,"type":36},"2026-02-01",{"date":66,"type":23},"2027-12",{"name":68,"class":43},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":24,"phases":78,"briefSummary":79,"conditions":80,"keywords":85,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":95,"leadSponsor":97,"locationsCount":44},"100626096","british-columbia-prescriber-feedback-program---antimicrobial-resistance-100626096","NCT07431190","British Columbia Prescriber Feedback Program - Antimicrobial Resistance","Building a National Framework to Combat Antimicrobial Resistance in Primary Care (CANBuild-AMR): Study Protocol for an Impact Evaluation of the British Columbia Prescriber Feedback Program","Practitioner Inclusion Criteria:\n\nRegistered in 2024 with the BC Medical Services Plan (MSP) with:\n\n* A valid MSP billing number;\n* Status of Salaried, Private Practice, Temporary Licence, or Post Graduate;\n* Prescribed \\>100 dispensed medications in 2024.\n\nExclusion Criteria:\n\n* Previously opted out of the Therapeutics Initiative Portrait program\n\nPatient Exclusion Criteria:\n\n* Age \\\u003C18 years at time of oral antibiotic dispensation;\n* Received PharmaCare benefits through the Palliative Care program at any time during the baseline or study period;\n* Hospitalized within 1 week prior to an antibiotic prescription at any time during the baseline or study period;\n* On chronic suppressive antibiotic therapy (≥90 days' supply of any antibiotic dispensed) during the baseline or study period",{"count":77,"type":23},7626,[56],"The goal of this study is to evaluate an educational intervention that aims to reduce the number of unnecessary antibiotics prescribed by family physicians and nurse practitioners in British Columbia, Canada.\n\nThe intervention materials include a confidential personalized prescribing \"portrait\" and an evidence-based educational summary (therapeutics letter), accompanied by an introduction letter.\n\nThe main research questions are:\n\n1. Will the intervention lead to a reduction in the overall number of antibiotics prescriptions started?\n2. Will the intervention lead to a reduction in the proportion of antibiotics prescribed that are likely unnecessary, especially prescriptions for upper respiratory tract infections, acute bronchitis, acute sinusitis?\n\nResearchers will conduct an intervention study with family physicians and nurse practitioners in British Columbia, Canada. Participant clinicians will be randomly assigned to one of two groups. The Early Group will consist of 80% of the participants and will receive the intervention (prescribing portrait, evidence summary, and introduction letter) at the start of the study. The Delayed Group will consist of 20% of participants and will receive the intervention about nine months later. This study design allows most practitioners to receive the intervention early while still allowing time to compare the two groups to assess the impact. To estimate the impact of the intervention, researchers will use administrative health data to compare the prescribing of the Early Group with prescribing of the Delayed Group.",[81,82,83,30,84],"Quality Improvement","Feedback","Prescribing","Antimicrobial Drug Resistance",[86,87,88,30,89],"Randomized controlled trial","Prescribing feedback","Quality improvement","Antimicrobial resistance","NOT_YET_RECRUITING","2026-02-17",{"date":93,"type":36},"2026-02-24",{"date":91,"type":23},{"date":96,"type":23},"2028-11-30",{"name":98,"class":43},"University of British Columbia",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":17,"sex":106,"minAge":19,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":110,"conditions":111,"keywords":116,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":44},"100481801","researchers-at-uc-san-diego-are-learning-about-the-benefits-of-human-milk-and-how-it-influences-infant-and-child-health-100481801","NCT05553743","Researchers At UC San Diego Are Learning About the Benefits of Human Milk and How It Influences Infant and Child Health","The UCSD Human Milk Biorepository","Inclusion Criteria:\n\n* Women who are 18 years old or older\n* Breastfeeding\n* Producing sufficient breast milk to donate an excess to the Biorepository\n\nExclusion Criteria:\n\n* Women under 18 years old","FEMALE",{"count":108,"type":23},5000,"OBSERVATIONAL","The purpose of the UCSD Human Milk Biorepository is to establish and maintain a repository of breast milk samples that can be used to learn more about how breast milk influences infant and child health.",[112,113,114,115,30],"Breastfeeding","COVID-19 Infection","COVID-19 Vaccine","Remdesivir",[112,113,114,115,30],"2025-01-28",{"date":119,"type":36},"2025-01-31",{"date":121,"type":36},"2014-03-27",{"date":123,"type":23},"2040-03",{"name":125,"class":43},"University of California, San Diego",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":106,"minAge":19,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":24,"phases":135,"briefSummary":136,"conditions":137,"keywords":141,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":152},"100465197","does-additional-use-of-preoperative-azithromycin-decrease-posthysterectomy-infections-100465197","NCT05337566","Does Additional Use of Preoperative Azithromycin Decrease Posthysterectomy Infections","Infections After Hysterectomy - a Placebo-controlled Study Comparing the Prophylactic Use of Azithromycin and Cefuroxime With Single Cefuroxime","Inclusion Criteria:\n\n* Women undergoing hysterectomy for benign indication in University Hospitals (Helsinki University Hospital, Turku University Hospital, Tampere University Hospital, Oulu University Hospital and Kuopio University Hospital) who have not any contraindications for azithromycin or cefuroxime.\n\nExclusion Criteria:\n\n* Inability to understand the study protocol.\n* Allergy for either cefuroxime or azithromycin.\n* Congenital or acquired prolonged Q-T-corrected interval. All the participants will be asked about arrhythmias and whether they have congenital arrhythmias in the family,\n* Electrocardiogram will be checked for all the participants.\n* Use of medicines that may prolong Q-T-corrected interval (class Ia arrhythmia medications, quinidine, procainamide, and class III arrhythmia medications dofetilide, amiodarone and sotalol).\n* Use of selective serotonin reuptake inhibitor medication and prolonged Q-T-corrected interval.",{"count":134,"type":23},2278,[56],"During hysterectomy bacteria may enter into the peritoneal cavity through vaginal opening and contaminate the healing tissues. The risk for deep infection after hysterectomy is about 5%. By reducing post-hysterectomy infections, it is possible to reduce individual burden of disease in addition to the direct and indirect financial costs. This study primary aim is to assess if prophylactic preoperative use of azithromycin in addition to generally used cefuroxime decreases post-hysterectomy infections as compared to cefuroxime only prophylaxis during 30 days after hysterectomy. Secondary aim is to assess if there is change in post-hysterectomy superficial infections, urinary tract infections, or post-operative fever between the cohorts and to report possible side-effects of the used antibiotics. In addition, the study finds out a possible role of bacterial vaginosis and microbiome n post-hysterectomy infections.",[138,139,30,140],"Infection Post Op","Hysterectomy","Prophylactic",[142],"postoperative, infection, hysterectomy, antibiotics","2024-08-19",{"date":145,"type":36},"2024-08-21",{"date":147,"type":36},"2022-09-05",{"date":149,"type":23},"2030-12",{"name":151,"class":43},"Helsinki University Central Hospital",6,{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":18,"minAge":161,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":24,"phases":165,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":180},"100514354","phase-3-nicu-antibiotics-and-outcomes-nano-follow-up-study-100514354","NCT05977400","NICU Antibiotics and Outcomes (NANO) Follow-up Study","NICU Antibiotics and Outcomes Follow-Up Study","NANO-FU","Inclusion Criteria: Families that have agreed to participate and are enrolled in the parent NANO trial will be eligible for the NANO follow-up study. There will be no exclusions for eligible children entering the follow-up study.\n\nParent NANO trial Criteria:\n\nI. Inclusion criteria: We will enroll newborn infants with gestational age of 23.0-30.6 weeks born to mothers 18 years or older at participating study sites. Only inborn infants at participating study sites will be eligible.\n\nII. Exclusion criteria:\n\n1. Infants at low risk for early onset sepsis-Infants born for maternal indications via caesarean section with rupture of membranes within 6 hours, without attempts to induce labor, and without concern for maternal infection\n2. Infants at high risk for early onset sepsis- Infants born to mothers with intrapartum fever (\\> 38ºC) or clinical diagnosis of chorioamnionitis (suspected or definite), infants born to mothers with proven Group B Streptococcus colonization or indication for intrapartum antibiotic prophylaxis that did not receive adequate antibiotic treatment according to specialty specific guidelines, (i.e., penicillin, ampicillin, cefazolin), infant born to mother with previous infant with GBS disease\u002Finfection\n3. Infants with respiratory insufficiency requiring invasive mechanical ventilation and fraction of inspired oxygen\\> 0.40 or non-invasive ventilation and fraction of inspired oxygen \\> 0.60 at time of randomization\n4. Infants with ongoing hemodynamic instability requiring vasopressors or more than one fluid bolus at time of randomization\n5. Clinician concern for sepsis due to physical exam findings or clinical history of mother or infant\n6. Major congenital anomalies\n7. Infants not anticipated to survive beyond 72 hours\n8. Infants who have received antibiotics prior to randomization.","23 Weeks","30 Weeks",{"count":164,"type":23},802,[166],"PHASE3","The NANO follow-up study is designed to determine whether a simple, cost-effective intervention- withholding antibiotics at birth- reduces clinically relevant outcomes such as behavioral and neurological impairment at 2 years of age. This study will be the largest study evaluating the effects of early antibiotics in children with comprehensive measures of neurodevelopment linked to genomic variants and microbiota interactions.",[169,30,170],"Premature Birth","Neurodevelopment","2023-07-28",{"date":173,"type":36},"2023-08-04",{"date":175,"type":23},"2024-04",{"date":177,"type":23},"2029-03",{"name":179,"class":43},"Sharp HealthCare",15,{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":24,"phases":190,"briefSummary":191,"conditions":192,"keywords":195,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":44},"100443301","preventive-therapy-of-postoperative-intra-abdominal-infection-based-on-serum-lactate-changes-100443301","NCT05052619","Preventive Therapy of Postoperative Intra-abdominal Infection Based on Serum Lactate Changes","A Prospective, Randomized Clinical Trial to Treat Intra-abdominal Infection Preventively After Pancreatic Surgery Based on Serum Lactate Changes","Inclusion Criteria:\n\n1. treatment by pancreatic resection, including pancreaticoduodenectomy, pancreatosplenectomy, total pancreatectomy, and other variant operations;\n2. revival in the intensive care unit (ICU) with standard serum lactate elution treatments after surgery instead of the operation room or general ward;\n3. availability of complete preoperative, intraoperative, and postoperative data;\n4. the peak serum lactate level in 24 hours after surgery \\>3.250 mmol\u002FL.\n\nExclusion Criteria:\n\n1. a history of surgical treatment of any upper abdominal lesions before the current hospital admission;\n2. the minimum mean arterial pressure \\\u003C65 mmHg during the operation;\n3. without written informed consents for the perioperative situation and related studies.",{"count":189,"type":23},297,[56],"Intra-abdominal infection is one of the most serious complications after pancreatic resection. The preventive use of antibiotics intraoperatively could reduce the incidence rate of postoperative intra-abdominal infection. According to the previous retrospective study, changes of serum lactate level on postoperative day1 could predict the incidence rate of postoperative intra-abdominal infection. This prospective RCT is to further validate and promote the findings and conclusion.",[193,194,30],"Postoperative Infection","Lactate",[196,197,198,199,200],"Serum lactate","Postoperative intra-abdominal infection","Preventive usage","Advanced antibioties","Strategy","2021-09-21",{"date":203,"type":36},"2021-09-27",{"date":205,"type":36},"2021-07-01",{"date":207,"type":23},"2026-07-01",{"name":209,"class":43},"Peking Union Medical College Hospital",{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":218,"enrollmentInfo":219,"targetDuration":4,"studyType":24,"phases":221,"briefSummary":222,"conditions":223,"keywords":225,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":44},"100286902","phase-4-prophylactic-oral-antibiotics-on-sinonasal-outcomes-following-endoscopic-transsphenoidal-surgery-for-pituitary-lesions-100286902","NCT03014687","Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions","A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Impact of Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions","POET","Inclusion Criteria:\n\n* Adult patient undergoing endoscopic surgery for resection of pituitary tumors for nonfunctioning adenoma, acromegaly, or prolactinoma\n* Adults \\>18 and \\\u003C85 years of age\n* English speaking and able to understand the ASK Nasal-12 and SNOT-22 scales\n* Free of any physical, mental, or medical condition which, in the opinion of the investigator, makes study participation inadvisable\n\nExclusion Criteria:\n\n* Anaphylaxis\u002Fintolerance to the study drugs\n* Cirrhosis, hepatitis\n* Any solid organ transplant or bone marrow transplant. And any patient felt to be immunocompromised by the investigators\n* Renal failure on dialysis\n* Any subject who is unwilling or unable to sign informed consent for the study\n* Pregnancy\n* Incarcerated patients\n* Cushing's disease\n* Rathke's Cleft cyst or pituitary cyst\n* History of chronic sinusitis\n* Anticipated use of nasal splints\n* Anticipated use of nasal septal flap\n* Active sinusitis\n* Nasal polyps\n* Previous sinus surgery\n* Concurrent antibiotics for another indication (i.e., urinary tract infection)\n* Immunodeficiency","84 Years",{"count":220,"type":23},116,[26],"To find out whether oral antibiotics given after transsphenoidal endoscopic surgery for pituitary adenoma improves sinus and nasal symptoms, reduces the incidence of infection (sinusitis), and helps mucosal healing in the nasal passages.",[30,224],"Pituitary Adenoma",[226],"transsphenoidal surgery","2018-08-13",{"date":229,"type":36},"2018-08-15",{"date":231,"type":36},"2017-07-01",{"date":233,"type":23},"2019-07",{"name":235,"class":43},"St. Joseph's Hospital and Medical Center, Phoenix"]